01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
22:52 , Oct 26, 2018 |  BC Extra  |  Company News

Management tracks: Principia, Orexo, Polyphor, MeiraGTx

Immunology and oncology company Principia Biopharma Inc. (NASDAQ:PRNB) hired Dolca Thomas as CMO. She succeeds Steve Gourlay, who will remain as a senior medical adviser through mid-2019. Thomas was VP and global head of translational...
01:59 , Dec 1, 2016 |  BC Innovations  |  Targets & Mechanisms

Not a peripheral story

By sourcing T cells directly from the pancreatic islets of Type I diabetes patients, rather than the standard method of taking blood samples, an academic team has provided an unprecedented view into the molecules that...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Company News

Apitope, Merck KGaA deal

Merck returned global rights to multiple sclerosis candidate ATX-MS-1467 to Apitope, terminating the partners’ 2009 deal. The vaccine containing four synthetic peptides derived from human myelin basic protein has completed a Phase IIa trial to...
07:00 , Oct 17, 2016 |  BC Extra  |  Company News

Merck KGaA returns rights to Apitope's vaccine

Apitope International N.V. (Diepenbeek, Belgium) said Merck KGaA (Xetra:MRK) returned global rights to multiple sclerosis candidate ATX-MS-1467 . Apitope did not disclose a reason for why Merck KGaA handed back the molecule. This quarter, Apitope...
07:00 , Oct 5, 2015 |  BC Week In Review  |  Financial News

Apitope completes venture financing

Apitope International N.V. , Diepenbeek, Belgium   Business: Autoimmune, Hematology, Ophthalmic   Date completed: 2015-09-29   Type: Venture financing   Raised: EUR12 million ($13.4 million)   Investors: Wales Life Sciences Investment Fund; Vesalius Biocapital Partners;...
07:00 , Sep 14, 2015 |  BC Week In Review  |  Clinical News

ATX-MS-1467: Completed Phase IIa enrollment

Merck completed enrollment in an open-label, German Phase IIa trial evaluating ATX-MS-1467 for 20 weeks. Patients’ ATX-MS-1467 doses are titrated during the first 4 weeks of treatment. Merck has exclusive, worldwide rights to develop and...
08:00 , Dec 22, 2014 |  BC Week In Review  |  Clinical News

ATX-F8-117 regulatory update

The European Commission granted Orphan Drug designation to ATX-F8-117 from Apitope to treat hemophilia A. The combination of 2 peptides derived from Factor VIII is in preclinical testing to treat and prevent Factor VIII inhibitor...
07:00 , Oct 16, 2014 |  BC Innovations  |  Translation in Brief

Translational tidbits

Big drive for big data In the last month, the NIH has pledged almost $100 million for big data programs aimed at making information usable and accessible to the wider research community and to create...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Company News

Apitope, KWS Biotest Ltd., Quintiles, GlaxoSmithKline autoimmune news

A consortium led by Apitope will receive funding of up to €6 million ($8.2 million) from the EU's Framework Programme 7 (FP7) to support a Phase I trial of Apitope's vaccine to treat Graves' disease....